Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX4 | Q9NPH5 | 14/20 | 0.77 |
| ▸ | CYBB | P04839 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3617185 | 0.89 | NOX4 (0.65) | NOX4CYBBCYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL3602788 | 0.87 | NOX4 (1.00) | NOX4CYBBCYP3A4TP53 | |
| SCHEMBL3616691 | 0.85 | NOX4 (0.59) | NOX4CYBBCYP3A4 | |
| SCHEMBL3615662 | 0.80 | NOX4 (0.53) | NOX4CYBBCYP2C9CYP2C19CYP3A4 | |
| SCHEMBL3614947 | 0.78 | NOX4 (0.84) | NOX4CYBBCYP3A4 | |
| SCHEMBL14950445 | 0.77 | NOX4 (0.83) | NOX4CYBBCYP3A4 | |
| SCHEMBL3615375 | 0.75 | NOX4 (0.52) | NOX4CYP2C9CYP2C19ALDH1A1KMT2A | |
| SCHEMBL3609140 | 0.74 | NOX4 (0.74) | NOX4CYBBCYP2C9CYP2C19CYP3A4 | |
| SCHEMBL3618610 | 0.74 | NOX4 (0.77) | NOX4CYBBCYP3A4MAPTKMT2A | |
| SCHEMBL13503057 | 0.73 | NOX4 (0.47) | NOX4CYBBCYP2C9CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073919-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-07-07 | — | — | US | claimed |
| EP-2545918-B1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-08-06 | — | — | EP | claimed |
| US-20130123256-A1 | Pyrazolo Pyridine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2013-05-16 | — | — | US | claimed |
| US-8389518-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2013-03-05 | — | — | US | claimed |
| EP-2545918-A1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2013-01-16 | — | — | EP | claimed |
| EP-2139477-B1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2012-12-12 | — | — | EP | claimed |
| US-20100048560-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2010-02-25 | — | — | US | claimed |
| EP-2139477-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2010-01-06 | — | — | EP | claimed |
| WO-2008113856-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2008-09-25 | — | — | WO | claimed |
| US-9073919-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073919-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073919-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-07-07 | — | — | US | disclosed |
| EP-2545918-B1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-08-06 | — | — | EP | disclosed |
| US-20130123256-A1 | Pyrazolo Pyridine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2013-05-16 | — | — | US | disclosed |
| EP-2139477-B1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2012-12-12 | — | — | EP | disclosed |
| US-20100048560-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100048560-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100048560-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2010-02-25 | — | — | US | disclosed |
| EP-2139477-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008113856-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048560-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX4, CYBB | NOX4 2/4885CYBB 3/4885CYP2C9 239/4885 |
| US-20130123256-A1 | Pyrazolo Pyridine Derivatives as NADPH Oxidase Inhibitors | NOX1, NOX4, CYBB | NOX4 2/4885CYBB 3/4885CYP2C9 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.